TY - JOUR
T1 - Concerns related to the COVID-19 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy
T2 - a Danish questionnaire survey
AU - Dyrberg Loft, Nikolai
AU - Halling, Anne-Sofie
AU - Iversen, Lars
AU - Vestergaard, Christian
AU - Deleuran, Mette
AU - Rasmussen, Mads Kirchheiner
AU - Zachariae, Claus
AU - Thyssen, Jacob P
AU - Skov, Lone
N1 - Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/12
Y1 - 2020/12
N2 - Patients with moderate-to-severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to Coronavirus disease 2019 (COVID-19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID-19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy.
AB - Patients with moderate-to-severe atopic dermatitis (AD) or psoriasis often require systemic immunomodulatory therapy. The uncertainty of the potential of these therapies to increase the risk of more serious illness due to Coronavirus disease 2019 (COVID-19) may have caused anxiety and led to treatment discontinuation. Therefore, we conducted an anonymous questionnaire on concerns of COVID-19 in patients with AD or psoriasis treated with systemic immunomodulatory therapy.
UR - http://www.scopus.com/inward/record.url?scp=85090994930&partnerID=8YFLogxK
U2 - 10.1111/jdv.16863
DO - 10.1111/jdv.16863
M3 - Comment/debate/letter to the editor
C2 - 32780487
SN - 0926-9959
VL - 34
SP - e773-e776
JO - Journal of the European Academy of Dermatology & Venereology
JF - Journal of the European Academy of Dermatology & Venereology
IS - 12
ER -